InvestorsHub Logo
Followers 5
Posts 420
Boards Moderated 0
Alias Born 12/10/2009

Re: None

Wednesday, 01/13/2016 9:56:39 AM

Wednesday, January 13, 2016 9:56:39 AM

Post# of 2020
http://zolmax.com/investing/zacks-can-fite-biopharma-ltd-nasdaqcanf-given-average-recommendation-of-strong-buy-by-analysts/303760/

Zacks: Can Fite Biopharma Ltd (NASDAQ:CANF) Given Average Recommendation of “Strong Buy” by Analysts

Posted by Bonnie Powley on Jan 12th, 2016 // No Comments


Can Fite Biopharma Ltd (NASDAQ:CANF) has been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus target price of $6.75 for the company and are forecasting that the company will post ($0.07) EPS for the current quarter, according to Zacks. Zacks has also given Can Fite Biopharma an industry rank of 53 out of 265 based on the ratings given to related companies.

Can Fite Biopharma (NASDAQ:CANF) traded down 3.33% during midday trading on Tuesday, reaching $2.32. The company’s stock had a trading volume of 97,383 shares. The company’s market cap is $24.98 million. Can Fite Biopharma has a 12 month low of $1.46 and a 12 month high of $64.71. The stock has a 50-day moving average price of $4.92 and a 200 day moving average price of $3.23.



Separately, HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Can Fite Biopharma in a report on Thursday, January 7th.

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CANF News